Targets Lifted

Price targets have been revisited upward by multiple firms. KeyBanc lifted its target to $35 from $30, while Truist Securities and Canaccord Genuity also upgraded their ratings to “Buy” and raised their targets. This collective optimism has pushed the share price to a new 52‑week high of $32 and a current trading level of $31.73, reflecting a 23.3 % year‑to‑date gain. The firm’s Zacks Rank sits at #1 (Strong Buy), a status it has maintained as earnings estimate revisions have increased 6.3 % over the past three months and the forward 12‑month Zacks Consensus EPS estimate climbed 7.14 %. Progyny’s Value Score is C, Growth Score A, and Momentum Score B, with a PEG ratio of 1.48 indicating moderate undervaluation potential. The Momentum Style Score is A, and the stock has surged 76.88 % over the last quarter and 29.35 % over the year, outpacing the S&P 500’s 10.61 % and 21.48 % gains respectively.